Navigation Links
New FDA Approved Drug To Treat Migraine

Axert has been approved by the FDA for the acute treatment of migraine with or without aura in adults.

Axert belongs to a class of drugs known as selective serotonin receptor agonists.Axert tablets contain almotriptan malate, a selective 5-hydroxytryptamine receptor agonist.//

This drug targets serotonin receptors and act against migraine headaches by inducing the constriction of blood vessels surrounding the brain.

Nausea, sleepiness, numbness, dry mouth and headache are the side effects associated with the use of Axert. In controlled trials, Axert showed a low percentage of side effects.

However this class of compounds has the potential to cause coronary vasospasm, and as a result Axert is not advised for patients with ischemic or vasospastic artery disease.

This drug is introduced by the pharmaceutical company, Pharmacia. Results of controlled clinical trials demonstrated that Axert was highly effective and well tolerated.

Axert is now an exciting new migraine therapy from Pharmacia, proven effective in the acute treatment of migraine.


'"/>




Page: 1

Related medicine news :

1. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
2. New FDA Approved Drug NATRECOR For Heart Failure Patients
3. New Oral Rinse For Gingivitis Approved By FDA
4. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
5. AIDS Generic Drugs Approved by FDA for Sale in US
6. FDA Approved Nerve-Stimulation Therapy Now Available In New York
7. Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA
8. Pfizer’s Eraxis Approved By The FD
9. Inhalers for Kids Was Approved By the FDA
10. Alcoholism Drug Vivitrol Approved By FDA
11. Drug Approved to Curb Alcohol Dependency
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/11/2016)... ... February 11, 2016 , ... ... seeking candidates for the Board of Commissioners. Individuals interested in volunteer board service ... with diversity of clinical practice settings and across allied health to contribute to ...
(Date:2/11/2016)... ... 11, 2016 , ... Life is known for throwing curves. It’s thrown quite ... gather once a year to play softball to raise money through Sun Health ... than 50 players who competed in this year’s softball tournament share a history of ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. announces the Infusion ... of Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ... the market, facilitates adherence to this standard with its easy to use, widely ...
(Date:2/11/2016)... Rock, AR (PRWEB) , ... February 11, 2016 , ... ... in their community by announcing a new fundraiser in support of a local boy ... also hopes the campaign will bring awareness to, and rally support for, all local ...
(Date:2/11/2016)... ... 11, 2016 , ... Be Well Medical Group (Be Well) is ... Town at 108 South Columbus St, Suite 201, Alexandria, VA. Be Well Medical Group ... in the convenience of their homes, offices or at the practices’ local office. It ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... -- Brain Cancer patients in the Mid-South ... West Cancer Center . Optune™, a portable ... cell replication causing death of cancer cells, is the ... show a significant extension in overall survival rates for ... Cancer Center is the only medical center in ...
(Date:2/11/2016)... 2016  AbbVie, a global biopharmaceutical company, announced ... to provide financial support for exceptional students living ... education goals. Fifteen scholars will be selected to ... The AbbVie Rheumatology Scholarship is currently accepting applications. ... corporate social responsibility, brand and communications, AbbVie. "By ...
(Date:2/11/2016)... , Feb. 11, 2016 PLAD, Inc. ... out 2016 with sales exceeding company targets, are adding ... received their trademark from the United States Patent and ... Clark , Chief Executive Officer of PLAD, Inc.  In ... Pennsylvania with two new customers, ...
Breaking Medicine Technology: